Cargando…
Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study
BACKGROUND: Daptomycin has been reported to cause artificial prolongation of prothrombin time (PT) by interacting with some test reagents of PT. This prolongation was particularly prominent with high concentrations of daptomycin in vitro. However, whether this prolongation is important in clinical s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387382/ https://www.ncbi.nlm.nih.gov/pubmed/28399872 http://dx.doi.org/10.1186/s12941-017-0203-3 |
_version_ | 1782520936831909888 |
---|---|
author | Saito, Makoto Hatakeyama, Shuji Hashimoto, Hideki Suzuki, Takumitsu Jubishi, Daisuke Kaneko, Makoto Kume, Yukio Yamamoto, Takehito Suzuki, Hiroshi Yotsuyanagi, Hiroshi |
author_facet | Saito, Makoto Hatakeyama, Shuji Hashimoto, Hideki Suzuki, Takumitsu Jubishi, Daisuke Kaneko, Makoto Kume, Yukio Yamamoto, Takehito Suzuki, Hiroshi Yotsuyanagi, Hiroshi |
author_sort | Saito, Makoto |
collection | PubMed |
description | BACKGROUND: Daptomycin has been reported to cause artificial prolongation of prothrombin time (PT) by interacting with some test reagents of PT. This prolongation was particularly prominent with high concentrations of daptomycin in vitro. However, whether this prolongation is important in clinical settings and the optimal timing to assess PT remain unclear. METHODS: A prospective clinical study was conducted with patients who received daptomycin for confirmed or suspected drug-resistant, gram-positive bacterial infection at a university hospital in Japan. PT at the peak and trough of daptomycin was tested using nine PT reagents. Linear regression analyses were used to examine the difference in daptomycin concentration and the relative change of PT-international normalized ratios (PT-INR). RESULTS: Thirty-five patients received daptomycin (6 mg/kg). The mean ± standard deviation of the trough and peak concentrations of daptomycin were 13.5 ± 6.3 and 55.1 ± 16.9 μg/mL, respectively. Twelve patients (34%) received warfarin. With five PT reagents, a significant proportion of participants experienced prolongation of PT-INR at the daptomycin peak concentration compared to the PT-INR at the trough, although the mean relative change was less than 10%. None of the participants clinically showed any signs of bleeding. A linear, dose-dependent prolongation of PT was observed for one reagent [unadjusted coefficient β 3.1 × 10(−3)/μg/mL; 95% confidence interval (CI) 2.3 × 10(−5)–6.3 × 10(−3); p = 0.048]. When patients were stratified based on warfarin use, this significant linear relationship was observed in warfarin users for two PT reagents (adjusted coefficient β, 6.4 × 10(−3)/μg/mL; 95% CI 3.5 × 10(−3)–9.3 × 10(−3); p < 0.001; and adjusted coefficient β, 8.3 × 10(−3)/μg/mL; 95% CI 4.4 × 10(−3)–1.2 × 10(−2); p < 0.001). In non-warfarin users, this linear relationship was not observed for any PT reagents. CONCLUSIONS: We found that a higher concentration of daptomycin could lead to artificial prolongation of PT-INR by interacting with some PT reagents. This change may not be clinically negligible, especially in warfarin users receiving a high dose of daptomycin. It may be better to measure PT at the trough rather than at the peak daptomycin concentration. |
format | Online Article Text |
id | pubmed-5387382 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53873822017-04-14 Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study Saito, Makoto Hatakeyama, Shuji Hashimoto, Hideki Suzuki, Takumitsu Jubishi, Daisuke Kaneko, Makoto Kume, Yukio Yamamoto, Takehito Suzuki, Hiroshi Yotsuyanagi, Hiroshi Ann Clin Microbiol Antimicrob Research BACKGROUND: Daptomycin has been reported to cause artificial prolongation of prothrombin time (PT) by interacting with some test reagents of PT. This prolongation was particularly prominent with high concentrations of daptomycin in vitro. However, whether this prolongation is important in clinical settings and the optimal timing to assess PT remain unclear. METHODS: A prospective clinical study was conducted with patients who received daptomycin for confirmed or suspected drug-resistant, gram-positive bacterial infection at a university hospital in Japan. PT at the peak and trough of daptomycin was tested using nine PT reagents. Linear regression analyses were used to examine the difference in daptomycin concentration and the relative change of PT-international normalized ratios (PT-INR). RESULTS: Thirty-five patients received daptomycin (6 mg/kg). The mean ± standard deviation of the trough and peak concentrations of daptomycin were 13.5 ± 6.3 and 55.1 ± 16.9 μg/mL, respectively. Twelve patients (34%) received warfarin. With five PT reagents, a significant proportion of participants experienced prolongation of PT-INR at the daptomycin peak concentration compared to the PT-INR at the trough, although the mean relative change was less than 10%. None of the participants clinically showed any signs of bleeding. A linear, dose-dependent prolongation of PT was observed for one reagent [unadjusted coefficient β 3.1 × 10(−3)/μg/mL; 95% confidence interval (CI) 2.3 × 10(−5)–6.3 × 10(−3); p = 0.048]. When patients were stratified based on warfarin use, this significant linear relationship was observed in warfarin users for two PT reagents (adjusted coefficient β, 6.4 × 10(−3)/μg/mL; 95% CI 3.5 × 10(−3)–9.3 × 10(−3); p < 0.001; and adjusted coefficient β, 8.3 × 10(−3)/μg/mL; 95% CI 4.4 × 10(−3)–1.2 × 10(−2); p < 0.001). In non-warfarin users, this linear relationship was not observed for any PT reagents. CONCLUSIONS: We found that a higher concentration of daptomycin could lead to artificial prolongation of PT-INR by interacting with some PT reagents. This change may not be clinically negligible, especially in warfarin users receiving a high dose of daptomycin. It may be better to measure PT at the trough rather than at the peak daptomycin concentration. BioMed Central 2017-04-11 /pmc/articles/PMC5387382/ /pubmed/28399872 http://dx.doi.org/10.1186/s12941-017-0203-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Saito, Makoto Hatakeyama, Shuji Hashimoto, Hideki Suzuki, Takumitsu Jubishi, Daisuke Kaneko, Makoto Kume, Yukio Yamamoto, Takehito Suzuki, Hiroshi Yotsuyanagi, Hiroshi Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study |
title | Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study |
title_full | Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study |
title_fullStr | Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study |
title_full_unstemmed | Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study |
title_short | Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study |
title_sort | dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387382/ https://www.ncbi.nlm.nih.gov/pubmed/28399872 http://dx.doi.org/10.1186/s12941-017-0203-3 |
work_keys_str_mv | AT saitomakoto dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT hatakeyamashuji dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT hashimotohideki dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT suzukitakumitsu dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT jubishidaisuke dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT kanekomakoto dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT kumeyukio dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT yamamototakehito dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT suzukihiroshi dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy AT yotsuyanagihiroshi dosedependentartificialprolongationofprothrombintimebyinteractionbetweendaptomycinandtestreagentsinpatientsreceivingwarfarinaprospectiveinvivoclinicalstudy |